Currently Viewing:
Currently Reading
Is Sickle Cell Trait Associated With Cognitive Impairment in African Americans?
May 25, 2019 – Wallace Stephens
Venetoclax Gains FDA Approval for Previously Untreated CLL, SLL
May 16, 2019 – Jaime Rosenberg
Finding the Trigger That Sets Off Growth of Hodgkin Lymphoma Cells
May 16, 2019 – Mary Caffrey
Study Identifies New Therapy Target For Blood Cancers in Mitochondria of Cancer Cells
May 11, 2019 – Jaime Rosenberg
Triple-Therapy Combo Without Chemo to Be Studied in DLBCL
May 10, 2019 – Mary Caffrey
IgL Translocation May Predict Poor Outcomes in Multiple Myeloma
May 02, 2019 – Jaime Rosenberg
Chemo, Then Radiotherapy, May Boost Survival for Patients With Advanced Hodgkin Lymphoma
May 02, 2019 – Mary Caffrey
A Slower, Gentler CAR T-Cell Therapy? USC Says a Small Study Shows It Could Work
April 24, 2019 – Mary Caffrey
CMS Proposes Increased Reimbursement for CAR T-Cell Therapy, Price Hikes for Rural Hospitals
April 24, 2019 – Jaime Rosenberg

Is Sickle Cell Trait Associated With Cognitive Impairment in African Americans?

Wallace Stephens
Analysis of findings from the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study found no association between sickle cell trait and cognitive impairment. 
An analysis of results from the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study shows that sickle cell trait (SCT) is not associated with cognitive impairment in a cohort of African Americans, according to findings reported in EClinicalMedicine.

Researchers hypothesized that adults at least 45 years old who carry SCT and have normal cognitive function would be more likely than SCT-free individuals to develop cognitive impairment over several years of follow-up, because there is a link between cognitive decline and those who have developed sickle cell anemia. “Sickle cell anemia may be associated with cognitive dysfunction, and some complications of sickle cell anemia might affect those with sickle cell trait,” researchers said in the abstract.

REGARDS was a longitudinal observational study that investigated racial and geographical variation in acquired cognitive impairment and incidence of stroke in the contiguous United States. Participants were randomly selected by mail, enrolled by telephone, and were visited in their homes between 2003 and 2007. REGARDS enrolled a total of 30,239 black and white Americans who were followed every 6 months.

REGARDS conducted global cognitive function testing using the Six-item Screener (SIS), a validated telephone-administered instrument for global cognitive function that assessed 3-item recall and orientation to year, month, and day of the week, which resulted in scores from 0 to 6 depending on correctly answered questions. A score that was less than or equal to 4 was considered positive for cognitive impairment. The SIS was first administered at baseline and then annually to all participants. The outcome of incident cognitive impairment was defined at the most recent assessment as of April 1, 2015, when the analysis data set was closed.

Participants completed a 3-test battery every 2 years that evaluated measures of learning, memory, and executive function. Validated tests assessed word list learning, delayed recall, semantic fluency, and phonemic fluency.

Black participants with the STC genotype who had available data at baseline and at least 1 follow-up SIS were included in the analysis. Participants who were white, had hemoglobin SS or SC genotype, developed incident stroke, or had baseline cognitive impairment were excluded.

Of the 7743 participants that were followed for a median period of 7.1 years, 85 of 583, or 14.6%, with SCT developed incident cognitive impairment, compared to 902 of 7160, or 12.6%, without SCT. When univariate analysis was conducted, the odds ratio of incident cognitive impairment was found to be 1.18 for those with SCT compared to those without it. The odds ratio was not impacted by adjustment.

Researchers determined that SCT was not associated with incidence of cognitive impairment or with changes over time in test scores included in the 3-test battery.

“In this large contemporary cohort of black Americans, there were no associations of SCT with incidence of cognitive impairment or with changes over time in test scores included in a 3-test battery assessing learning, memory, and semantic and phonemic fluency. These findings suggest that, unlike findings to date in SCA, biological consequences of SCT do not appear to cause cognitive dysfunction,” researchers concluded.

Researchers suggested a detailed study that examines cognitive impairment in a younger cohort of adults or in children should be conducted to confirm their findings.


Cahill CR, Leach, JM, McClure LA, et al. Sickle cell trait and risk of cognitive impairment in African-Americans: the REGARDS cohort [published online May 23, 2019]. EClinicalMedicine. 2019. doi:

Related Articles

Study Documents Chronic Pain Associated With Sickle Cell Disease
NIH Seeks 'Self' Cure in Patients With Sickle Cell Disease
Crizanlizumab Can Reduce or Delay Pain Crises Events in Patients With Sickle Cell Disease
Study Confirms Safe Use of Opioids for Pain Control in Sickle Cell Disease
Bill Addressing Sickle Cell Disease/Heritable Blood Disorders Signed Into Law
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up